TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Recommendation of “Moderate Buy” from Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has been assigned an average rating of “Moderate Buy” from the ten brokerages that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $125.11.

A number of equities analysts have recently weighed in on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Tuesday, June 3rd. Canaccord Genuity Group reissued a “buy” rating and issued a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Piper Sandler reissued an “overweight” rating and issued a $145.00 price target (up from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Finally, Oppenheimer increased their price target on TransMedics Group from $125.00 to $130.00 and gave the company an “outperform” rating in a research report on Friday, May 9th.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director David Weill sold 732 shares of the firm’s stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the completion of the transaction, the director now owns 12,134 shares in the company, valued at $1,503,159.92. This trade represents a 5.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Anil P. Ranganath sold 686 shares of the firm’s stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the transaction, the insider now owns 13,955 shares of the company’s stock, valued at approximately $1,950,909. This represents a 4.69% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 12,418 shares of company stock worth $1,512,613. 7.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in TMDX. NBC Securities Inc. purchased a new stake in shares of TransMedics Group in the 1st quarter valued at about $25,000. Smartleaf Asset Management LLC raised its holdings in shares of TransMedics Group by 44.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock valued at $30,000 after acquiring an additional 135 shares in the last quarter. Atlas Capital Advisors Inc. purchased a new stake in shares of TransMedics Group in the 4th quarter valued at about $31,000. Quarry LP raised its holdings in shares of TransMedics Group by 88.5% in the 1st quarter. Quarry LP now owns 592 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares in the last quarter. Finally, Hager Investment Management Services LLC raised its holdings in shares of TransMedics Group by 38.3% in the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company’s stock valued at $50,000 after acquiring an additional 205 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $141.96 on Tuesday. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group has a twelve month low of $55.00 and a twelve month high of $177.37. The stock’s 50 day moving average is $110.23 and its 200-day moving average is $82.77. The firm has a market capitalization of $4.80 billion, a price-to-earnings ratio of 151.02 and a beta of 2.10.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.29 by $0.41. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. During the same period in the prior year, the firm earned $0.35 earnings per share. TransMedics Group’s revenue for the quarter was up 48.2% on a year-over-year basis. Sell-side analysts forecast that TransMedics Group will post 1 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.